Institute of Biotechnology and Antibiotics (IBA)

exultantmynabirdBiotechnology

Dec 14, 2012 (4 years and 11 months ago)

204 views

Institute of Biotechnology and
Antibiotics
(IBA)

Presented by Małgorzata Kęsik

Assistant Professor at IBA


Institute of Biotechnology and
Antibiotics
(IBA)



I
s a State research and development centre

established in 1985 by the Minister of Industry.




Its

activity is associated with health care and
pharmaceutical industry.




E
mploys 125 people, including 2
6

scientists.

The IBA Bioton Group

Institute of Biotechnology
and Antibiotics
has been
taken over and developed by Bioton.

Currently IBA and Bioton forme IBA
-
BIOTON
Group.

IBA
-
BIOTON Group is a Polish leading
pharmaceutical producer.


The research work at IBA

focuses on:


methods of synthesizing new antibiotics,


selection of highly effective strains of
microorganisms for the production of antibiotics,


the improvement of antibiotic biosynthesis
processes,


the study of mechanisms of transmitting
antibiotic
-
resistant genes in bacteria,


development of new preparations for diagnosis
based on monoclonal antibodies.



The research work at IBA

focuses on (2):


genetic engineering of new gene expression
systems,


genome diagnostics,


manufacturing of biologically active high purity
compounds with protein structure (e.g.:
recombinant human insulin, growth hormone and
interferon)


R
ecombinant

human insulin


2000
-
2005
:

Completion

of

a

long
-
term

team

project

on

recombinant

human

insulin

manufacturing

technology
.



B
iosynthetic

human

insulin

solution,

isophane

biosynthetic

human

insulin

and

its

mixtures

(
17

pharmaceutical

forms

in

total)

were

authorised

for

marketing

in

Poland

and

implemented

in

production

by

the

Bioton

company

under

the

Gensulin

trade

name
.


IBA

manufactures three

important antineoplastic
medications:



Biorubina® (doxorubicin)

-

anthracycline antibiotic
used in solid tumour therapy haemopoietic and
lymphatic sarcomas and neoplasms.


Bioepicyna® (epirubicin)

-

anthracycline antibiotic
used in various neoplasms


Biodribin® (cladribine)



deoxyadenosine
nucleoside derivative, used in hairy cell
leukaemia, chronic lymphocytic leukaemia and
non
-
Hodgkin lymphoma.

I
nternational cooperation


P
articipat
ion

in

international MolCoNet project
,
financed by the E
U

(
coordinated by Milan
University
)
.


The p
roject
is
to share experiences in utilisation
of logical operations with DNA.



P
roject partici
pants:

institutes and universities
from

Austria, France, Spain, the Netherlands,
Moldova, Rumania, Great Britain and Italy.

D
epartment of

B
ioengineering


research on

plasmids, aimed at producing own
high
-
efficiency protein expression systems,


research on

genome’s mobile elements and
integrons in drug resistance development in
bacteria,


research aimed at recombinant viral antigen
production and application as oral subunit
vaccines


O
ffer



G
enetic

E
ngineering



Construction of
Escherichia coli

working strains
producing specific protein or peptide medications
based on own expression or other vectors
patented by IBA.


Working strain stability testing.


Strain stability or protein production enhancement
by implementing genetic changes in vectors.


Periodic control of protein coding sequence in the
expression vector as required by the Good
Laboratory Practice principles.

O
ffer



G
enetic

E
ngineering (2)


Development of separate analytical methods for
each medicinal product, including quantitative
determination of contamination with host protein,
plasmid and genome DNA required by the
European Medicines Agency, determination or
development of the ELISA test and production of
monoclonal antibodies used in the test.


Biological activity test of the protein medications
in cell cultures.




O
ffer



G
enetic

E
ngineering (3):


Development of immunological ELISA tests to
determine other impurities in tested medications,
e.g. residual enzymes used in production.


Orders for developing purification methods for
specific proteins made by working
E. coli

strains
with respect to limitations associated with
process scale
-
up from beaker to industrial scale
.

Thank you

for your attention


Ph.D. Małgorzata Kęsik

Institute of Biotechnology and Antibiotics

kesikm@iba.waw.pl